396 related articles for article (PubMed ID: 15200414)
1. Plasmin is not protective in experimental renal interstitial fibrosis.
Edgtton KL; Gow RM; Kelly DJ; Carmeliet P; Kitching AR
Kidney Int; 2004 Jul; 66(1):68-76. PubMed ID: 15200414
[TBL] [Abstract][Full Text] [Related]
2. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.
Zhang G; Kernan KA; Collins SJ; Cai X; López-Guisa JM; Degen JL; Shvil Y; Eddy AA
J Am Soc Nephrol; 2007 Mar; 18(3):846-59. PubMed ID: 17267741
[TBL] [Abstract][Full Text] [Related]
3. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
[TBL] [Abstract][Full Text] [Related]
4. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.
Oda T; Jung YO; Kim HS; Cai X; López-Guisa JM; Ikeda Y; Eddy AA
Kidney Int; 2001 Aug; 60(2):587-96. PubMed ID: 11473641
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L
Kidney Int; 2005 Dec; 68(6):2651-66. PubMed ID: 16316341
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy.
Zhang G; Kim H; Cai X; López-Guisa JM; Alpers CE; Liu Y; Carmeliet P; Eddy AA
J Am Soc Nephrol; 2003 May; 14(5):1254-71. PubMed ID: 12707394
[TBL] [Abstract][Full Text] [Related]
7. Endogenous urokinase lacks antifibrotic activity during progressive renal injury.
Yamaguchi I; Lopez-Guisa JM; Cai X; Collins SJ; Okamura DM; Eddy AA
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F12-9. PubMed ID: 17356128
[TBL] [Abstract][Full Text] [Related]
8. Macrophage infiltration and renal damage are independent of matrix metalloproteinase 12 in the obstructed kidney.
Abraham AP; Ma FY; Mulley WR; Ozols E; Nikolic-Paterson DJ
Nephrology (Carlton); 2012 May; 17(4):322-9. PubMed ID: 22257277
[TBL] [Abstract][Full Text] [Related]
9. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis.
Gonzalez J; Klein J; Chauhan SD; Neau E; Calise D; Nevoit C; Chaaya R; Miravete M; Delage C; Bascands JL; Schanstra JP; Buffin-Meyer B
Exp Biol Med (Maywood); 2009 Dec; 234(12):1511-8. PubMed ID: 19934371
[TBL] [Abstract][Full Text] [Related]
10. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction.
Yao L; Wright MF; Farmer BC; Peterson LS; Khan AM; Zhong J; Gewin L; Hao CM; Yang HC; Fogo AB
Nephrol Dial Transplant; 2019 Dec; 34(12):2042-2050. PubMed ID: 31071225
[TBL] [Abstract][Full Text] [Related]
12. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice.
Kurata K; Maruyama S; Kato S; Sato W; Yamamoto J; Ozaki T; Nitta A; Nabeshima T; Morita Y; Mizuno M; Ito Y; Yuzawa Y; Matsuo S
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1510-7. PubMed ID: 19934446
[TBL] [Abstract][Full Text] [Related]
13. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Lijnen HR; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1035-45. PubMed ID: 9672063
[TBL] [Abstract][Full Text] [Related]
14. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Higashi K; Oda T; Kushiyama T; Hyodo T; Yamada M; Suzuki S; Sakurai Y; Miura S; Kumagai H
Nephrology (Carlton); 2010 Apr; 15(3):327-35. PubMed ID: 20470302
[TBL] [Abstract][Full Text] [Related]
15. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
16. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
Liu Z; Li N; Diaz LA; Shipley M; Senior RM; Werb Z
J Clin Invest; 2005 Apr; 115(4):879-87. PubMed ID: 15841177
[TBL] [Abstract][Full Text] [Related]
17. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.
Matsuo S; López-Guisa JM; Cai X; Okamura DM; Alpers CE; Bumgarner RE; Peters MA; Zhang G; Eddy AA
Kidney Int; 2005 Jun; 67(6):2221-38. PubMed ID: 15882265
[TBL] [Abstract][Full Text] [Related]
18. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy.
Yang J; Liu Y
Am J Physiol Renal Physiol; 2003 Feb; 284(2):F349-57. PubMed ID: 12529273
[TBL] [Abstract][Full Text] [Related]
19. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
20. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
Moon JA; Kim HT; Cho IS; Sheen YY; Kim DK
Kidney Int; 2006 Oct; 70(7):1234-43. PubMed ID: 16929250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
